Portola Pharma (PTLA) Misses Q4 EPS by 11c

Portola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($1.23), $0.11 worse than the analyst estimate of ($1.12). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $2.43 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Raymond James on Malibu Boats (MBUU): 'continued soft retail environment'
• BofA turns S&P 500 signals from red to yellow: What to buy now